GlassScriptPhysician profile
Maci Mcqueary
NPI 1104430297
$1,141.49
in general payments reported to CMS, 2019-2025
22 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $92.88 · 2022: $87.03 · 2023: $335 · 2024: $344 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $961.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $182.04 | 2023-2025 | |
| Novo Nordisk INC | $157.49 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $120.78 | 2021-2024 | Mounjaro, Zepbound, Emgality |
| Amgen INC. | $86.08 | 2022-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $64.06 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Alkermes, INC. | $59.39 | 2024-2025 | Vivitrol |
| Axsome Therapeutics, INC. | $55.32 | 2024-2025 | Auvelity |
| Astellas Pharma US INC | $47.13 | 2023-2024 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $45.47 | 2024-2025 | Rexulti |
| Pfizer INC. | $43.18 | 2021-2025 | |
| Shield Therapeutics INC | $40.78 | 2024 | |
| Idorsia Pharmaceuticals US INC | $34.51 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $33.49 | 2023-2024 | Gemtesa |
| Glaxosmithkline, LLC. | $28.05 | 2024 | Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $25.32 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $23.12 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.25 | 2025 | Trintellix |
| Merck Sharp & Dohme LLC | $17.13 | 2022 | |
| Amarin Pharma, INC. | $15.50 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.33 | 2023 | |
| Vanda Pharmaceuticals INC. | $15.29 | 2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.78 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maci Mcqueary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.